Acute and long-term alterations in immediate early gene expression by antipsychotic drugs: Downstream genomic targets, behavioral correlates, and role of D2, D3, and D4 receptors

Pharmacological Regulation of Gene Expression in the CNS

Volumn , Issue , 2017, Pages 25-50

  Merchant, Kalpana ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878688569     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203711149     Document Type: Chapter

References (111)

1. Creese, I., Burt, D.R. and Snyder, S.H., Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs, Science, 192, 481,1976.
2. Seeman, P., Lee, T., Chau-Wong, M. and Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors, Nature, 261, 717, 1976.
3. Perutka, S.J. and Snyder, S.H., Relationship of neuroleptic drug effects to brain dopamine, serotonin, adrenergic and histamine receptors and clinical potency, Am. J. Psychiatr., 137, 1518, 1980.
4. Meltzer, H.Y., Lee, M.A. and Ranjan, R., Recent advances in the pharmacotherapy of schizophrenia, Acta Psychiatr. Scand., 90 (Suppl. 384), 95, 1994.
5. Kane, J.M. and Freeman, H.L., Towards more effective antipsychotic treatment, Br. J. Psychiatr., 165 (Suppl. 25) 22, 1994.
6. Baldessarini, R.J. and Frankenburg, F.R., Clozapine: a novel antipsychotic drug, N. Engl. J. Med., 324, 746, 1991.
7. Deutch, A.Y., Moghaddam, B., Innis, R.B., Krystal, J.H., Aghajanian, G.K., Bunney, B.S. and Charney, D.S., Mechanisms of actions of atypical antipsychotic drugs: implications for novel therapeutic strategies of schizophrenia, Schizophrenia Res., 4, 121, 1991.
8. Kerwin, R.W., The new atypical antipsychotics. A lack of extrapyramidal side effects and new routes in schizophrenia research, Br. J. Psychiatr., 164, 141, 1994.
9. Dolan, R.J., Functional imaging and the neurobiology of the psychoses, Neurosciences 7, 165, 1995.
10. Kotrla, K.J. and Weinberger, D.R., Brain imaging in schizophrenia, Annu. Rev. Med., 46, 113, 1995.
11. Morgan, J.I. and Curran, T., Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun, Annu. Rev. Neurosci., 14, 421, 1991.
12. Dragunow, M. and Faull, R.L.M., The use of c-fos as a metabolic marker in neuronal pathway tracing, J. Neurosci. Methods, 29, 261, 1989.
13. Chiu, R., Boyle, W., Meek, J., Smeal, T., Hunter, T. and Karin, M., The c-fos protein interacts with c-jun/AP-1 to stimulate transcription of the AP-1 responsive genes, Cell, 54, 541, 1988.
14. Nakabeppu, Y. and Nathans, D., A naturally occurring truncated form of FosB that inhibits Fos/Jun transcription activity, Cell, 64, 751, 1991.
15. Christy, B. and Nathans, D., DNA binding site of growth factor-inducible protein, Zif268, Proc. Natl. Acad. Sci. U.S.A., 86, 8737, 1989.
16. Miller, J.C., Induction of c-fos mRNA expression in the rat striatum by neuroleptic drugs, J. Neurochem., 54, 1453, 1990.
17. Dragunow, M., Robertson, G.S., Faull, R.L.M., Robertson, H.A. and Jansen, K., D2 dopamine receptor antagonists induce Fos. and related proteins in rat striatal neurons, Neuroscience, 37, 287, 1990.
18. Nguyen, T.V., Kosofosky, B.E., Birnbaum, R., Cohen, B.M. and Hyman, S.E., Proc. Natl. Acad. Sci. U.S.A., 89, 4270, 1992.
19. Robertson, G.S. and Fibiger, H.C., Neuroleptics increase c-fos expression in the forebrain, Contrasting effects of haloperidol and clozapine, Neuroscience, 46, 315, 1992.
20. Deutch, A.Y., Lee, M.C. and Iadarola, M.J., Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression, the nucleus accumbens shell as a locus of antipsychotic action, Mol. Cell. Neurosci., 3, 332, 1992.
21. Carelli, R.M. and West, M.O., Representation of the body by single neurons in the dorsolateral striatum of the awake unrestrained rat, J. Comp. Neurol., 309,231,1991.
22. Merchant, K.M. and Dorsa, D.M., Differential induction of neurotensin and c-fos gene expression by typical vs. atypical antipsychotics, Proc. Natl. Acad. Sci. U.S.A., 90, 3447, 1993.
23. Ogren, S.-O., Hall, H., Kohler, C., Magnuson, O., Lindbom, L.-O., Angeby, K. and Florvall, L., Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain, Eur.]. Pharmacol., 102, 459, 1984.
24. Mendelwicz, J., de Bleeker, E., Cosyns, R, Deleu, G., Lostra, F., Masson, A., Martens, C., Parent, M., Peuskens, J., Suy, E., de Wile, J., Wilmotte, J. and Norgard, J., A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders, Acta Psychiatr. Scand., 82 (Suppl. 358), 138, 1990.
25. Kohler, C., Hall, H., Magnusson, O., Lewander, T. and Gustafsson, K., Biochemical pharmacology of the atypical neuroleptic remoxipride, Acta Psychiatr. Scand., 82 (Suppl. 358), 27, 1990.
26. Walinder, J. and Holm, A.C., Experience of long-term treatment with remoxipride: efficacy and tolerability, Acta Psychiatr. Scand., 82 (Suppl. 358), 158, 1990.
27. Ahlfors, U.G., Rimon R., Appleberg, B., Hagert, U., Harma, R, Katila, H., Mahl-anen, A., Mehtonen, O.-R, Naukkarinen, H., Outakoski, J., Rantanen, H., Sorri, A., Taminnen, T., Tolvanen, E. and Holm, A.-C., Remoxipride and haloperidol in schizophrenia: a double bind multicentre study, Acta Psychiatr. Scand., 82 (Suppl. 358), 99, 1990.
28. Lewander, T., Overcoming the neuroleptic-induced deficit syndrome, clinical observations with remoxipride, Acta Psychiatr. Scand. 89 (Suppl. 380) 64, 1994.
29. Krieskott, J., Behavioral Pharmacology of Antipsychotics, in Handbook of Experimental Pharmacology, Vol. 55, Hoffmeister, F. and Stille, G., Eds., Springer-Verlag, Berlin, 1980, p. 59.
30. Baldessarini, R.J., Drugs and the Treatment of Psychiatric Disorders, in Goodman and Gillman's The Pharmacological Basis of Therapeutics, Goodman, A.G., Rail, T.W., Nies, A.S. and Taylor, R, Eds., Pergamon Press, New York, 1990, p. 383.
31. Robertson, G.S., Matsumura, H. and Fibiger, H.C., Induction of Fos-like immu-noreactivity in the forebrain as predictors of atypical antipsychotic activity, J. Pharmcol. Exp. Ther., 271, 1058, 1994.
32. MacGibbon, G.A., Lawlor, P.A., Bravo, R. and Dragunow, M., Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja, Mol. Brain Res., 23, 21, 1994.
33. Fink-Jensen, A. and Kristensen, P, Effects of typical and atypical neuroleptics on Fos protein expression in rat forebrain, Neurosci. Lett., 182, 115, 1994.
34. Sebens, J.B., Koch, T., Ter Horst, G.J. and Korf, J., Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment, Eur. J. Pharmacol, 273, 175, 1995.
35. 34a. Deutch, A.Y., Ongur, D. and Duman, R.S., Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus; a novel locus of antipsychotic drug action, Neuroscience, 66, 337, 1995.
36. Merchant, K.M., Dobie, D.J. and Dorsa, D.M., Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs, Ann. N.Y. Acad. Sci., 668, 54, 1992.
37. Guo, N., Robertson, G.S. and Fibiger, H.C., Scopolamine attenuates haloperidol-induced c-fos expression in the striatum, Brain Res., 588, 164, 1992.
38. Robertson, G.S., Vincent, S.R. and Fibiger, H.C., D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopaliidal neurons, Neuroscience, 49, 285, 1992.
39. Graybiel, A.M., Neurotransmitters and neuromodulators in the basal ganglia, Trends Neurosci. 13, 244, 1990.
40. Sugimoto, T. and Mizuno, N., Neurotensin in projection neurons of the striatum and nucleus accumbens, with reference to coexistence with enkephalin and GABA: an immunohistochemical study in the cat, J. Comp. Neurol, 257, 383, 1987.
41. DeLong, M.R., Primate models of movement disorders of basal ganglia circuitry, Trends Neurosci., 13, 280, 1990.
42. Albin, R.L., Young, A.B. and Penney, J.B., The functional anatomy of basal ganglia disorders, Trends Neurosci., 12, 366, 1989.
43. Sonnenberg, J.L., Rauscher, F.J., Morgan, J.I. and Curran, T., Regulation of proenkephalin by Fos and Jun, Science, 246, 1622, 1989.
44. Tang, F., Costa, E. and Schwartz, J.P., Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks, Proc. Natl. Acad. Sci., U.S.A., 80, 3841, 1983.
45. Sabol, S.L., Yoshikawa, K. and Hong, J.-S., Regulation of Methionine-enkephalin messenger RNA in rat striatum by haloperidol and lithium, Biochem. Biophys. Res. Commun., 113, 391, 1983.
46. Angulo, J.A., Cadet, J.L., Woolley, C.S., Suber, F. and McEwen, B.S., Effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the rat striatum and nucleus accumbens of the rat, J. Neurochem., 54,1889,1990.
47. Sivam, S.P., Strunk, C., Smith, D.R. and Hong, J.S., Proenkephalin-A gene regulation in the rat striatum: influence of lithium and haloperidol, Mol. Pharmacol., 30, 186, 1991.
48. Mercugliano, M., Sailer, C., Salama, A., UTrichard, D. and Chesselet, M.-F., Clozapine and haloperidol have differential effects on glutamic acid decarboxylase mRNA in pallidal nuclei of the rat, Neuropsychopharmacology, 6, 179, 1992.
49. Konradi, C., Kobierski, L.A., Nguyen, T.V., Heckers, S. and Hyman, S.E., The rat cAMP-response-element-binding protein interacts, but Fos protein does not interact, with proenkephalin enhancer in rat striatum, Proc. Natl. Acad. Sci., U.S.A., 90, 7005, 1993.
50. Merchant, K.M., Miller, M.A., Ashleigh, E.A., and Dorsa, D.M., 1991, Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain, Brain Res., 540: 311-314.
51. Augood, S.J., Kiyama, H., Faull, R.L.M. and Emson, PC., Differential effects of acute dopaminergic D1 and D2 receptor antagonists on proneurotensin mRNA expression in rat striatum, Mol. Brain Res., 9, 341, 1991.
52. Merchant, K.M., Dobner, PR. and Dorsa, D.M., Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum, J. Neurosci., 12, 652, 1992.
53. Govoni, S., Hong, J.S., Yang, H.Y.-T. and Costa, E., Increase of neurotensin content elicited by neuroleptics in the nucleus accumbens, J. Pharmacol. Exp. Ther., 215, 413, 1980.
54. Merchant, K.M., Bush, L.G., Gibb, J.W. and Hanson, G.R., Dopamine D-2 receptors exert tonic regulation of discrete neurotensin systems of the rat brain, Brain Res., 500, 21, 1989.
55. Frey, P, Fuxe, K., Eneroth, P. and Agnati, L., Effects of acute and long-term treatment with neuroleptics on regional telencephalic neurotensin levels in the male rat, Neurochem. Int., 8, 429, 1986.
56. Levant, B., Bissette, G. and Nemeroff, C.B., Neurotensin, in Neuropeptides in Psychiatry, Nemeroff C.B., Ed., APA Press, Washington, 1987, p., 149-168.
57. Kislauskis, E. and Dobner, P.R., Mutually dependent response elements in the cis-regulatory region of the neurotensin/neuromedin N gene integrate environmental stimuli in PC12 cells, Neuron, 4, 783, 1990.
58. Merchant, K.M. and Miller, M.A., Coexpression of neurotensin and c-fos mRNAs in rat neostriatal neurons following acute haloperidol, Mol. Brain Res., 23,271,1994.
59. Robertson, G.S., Tetzlaff, W., Bedard, A., St. Jean, M. and Wigle, N., c-fos mediates antipsychotic-induced gene expression in the rodent striatum, Neuroscience, 67, 325, 1995.
60. Merchant, K.M., c-fos antisense oligonucleotide specifically attenuates haloperi-dol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum. Mol. Cell Neurosci., 5, 336, 1994.
61. Heimer, L., Zahm, D.S., Churchill, L., Kalivas, P.W. and Wohltmann, C., Specificity in the projection patterns of accumbal core and shell, Neuroscience, 41, 89, 1991.
62. Zahm, D.S. and Heimer, L., Ventral striatopallidal parts of the basal ganglia in the rat: I. Neurochemical compartmentation as reflected by distribution of neurotensin and substance P immunoreactivity, J. Comp. Neurol, 272, 516, 1988.
63. Nemeroff, C.B. and Cain, S.T., Neurotensin-dopamine interactions in the CNS, Trends Pharmacol Sci., 6, 201, 1985.
64. Kalivas, P.W., Burgess, S.K., Nemeroff, C.B. and Prange, A.J., Jr., Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area, Neuroscience, 8, 495.
65. Erin, G.N., Birkemo, L.S., Nemeroff, C.B. and Prange, A.J., Jr., Neurotensin blocks certain amphetamine-induced behaviours, Nature, 291, 73, 1981.
66. Widerlov, E., Lindstrom, L.H., Besev, G., Manberg, P.J., Nemeroff, C.B., Breese, G.R., Kizer, J.S. and Prange, A.J., Jr., Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients, normalization after neuroleptic treatment, Am. J. Psychiatr., 139
67. Wolf, S.S., Hyde, T.M., Moody, T.W., Saunders, R.C., Weinberger, D.R. and Kleinman, J.E., Autoradiographic characterization of 1251-neurotensin binding sites in human entorhinal cortex, Brain Res. Bull, 35, 353, 1994.
68. Guo, N., Vincent, S.R. and Fibiger, H.C., Dopamine D3 receptors mediate clozapine-induced c-fos expression in the forebrain. Abstr. Soc. Neurosci., 21,1707,1995.
69. Weinberger, D.R., Berman, K.F. and Zee, R.F., Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatr., 43: 114, 1986.
70. Deutch, A.Y. and Duman, R.S., The effects of antipsychotic drugs on prefrontal cortical Fos expression; cellular localization and pharmacological characterization, Neuroscience, 70, 377, 1995.
71. Merchant, K.M., Figur, L.M., and Evans, D.L. Antipsychotic drug-induced expression of c-fos mRNA in the medial prefrontal cortex: role of D2 vs. D3 receptors, Cerebral Cortex, 6, 1, 1996.
72. Christy, B. and Nathans, D., DNA binding site of the growth factor-inducible protein, Zif268, Proc. Natl Acad. Sci. U.S.A., 86: 8737, 1989.
73. Herdegen, T., Kovary, K., Buhl, A., Bravo, R., Zimmerman, M. and Gass, P, Basal expression of the inducible transcription factors c-jun, JunB, JunD, c-Fos, FosB and Krox-24 in the adult rat brain, J. Comp. Neurol, 354, 39, 1995.
74. Daunais, J.B. and McGinty, J.F., The effects of D1 or D2 dopamine receptor blockade on Zif268 and prodynorphin gene expression in rat forebrain following a short-term cocaine binge, Mol. Brain Res., 35, 237, 1996.
75. Shibata, K., Yamada, K. and Furukawa, T., Possible neurochemical mechanisms involved in neurotensin-induced catalepsy in mice, Psychopharmacology, 91, 288, 1987.
76. Janssen, P.A., Niemegeers, C.J. and Schellekens, K.H., Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data?, Arz-neim Forsch., 15, 104, 1965.
77. Lappalainen, J., Hietala, J. and Syvalahti, J., Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration, Psychopharmacology, 98, 472, 1989.
78. Ossowska, K., Karacz, M., Wardas, J. and Wolfarth, S., Striatal and nucleus accum-bens D1/D2 dopamine receptors in neuroleptic catalepsy, Eur. J. Pharmacol, 182, 327, 1990.
79. Merchant, K.M., Dobie, D.J., Totzke, M., Aravagiri, M. and Dorsa, D.M., Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J. Pharmcol. Exp. Then, 271, 460, 1994.
80. Merchant, K.M. and Dobie, D.J., Correlation between tolerance in neurotensin gene expression and cataleptic response in rats following continuous haloperidol treatment, Abstr. Soc. Neurosci., 19, 1364, 1993.
81. Campbell, A. and Baldessarini, R.J. Tolerance to behavioral effects of haloperidol, life Sci., 29, 1341, 1981.
82. Delfs, J.M., Ellison, G.D., Reisine, T. and Chesselet, M.-F., regulation of p-opioid mRNA in rat globus pallidus: effects of enkephalin increases induced by short-and long-term haloperidol administration, J. Neurochem., 63, 777, 1994.
83. Ungerstedt, U. and Arbuthnott, G.W., Quantitative recording of rotational behavior in rats after 6-hydroxy dopamine lesions of the nigrostriatal system, Brain Res., 24, 485, 1970.
84. Merchant, K.M., Similar to typical antipsychotics, nigrostriatal dopamine lesions induce neurotensin gene expression in the dorsolateral striatum, Abstracts, Annual Meeting of American College of Neuropsychopharmacology, 108, 1992.
85. Nisenbaum, L.K., Kitai, S.T. and Gerfen, C.R., Dopaminergic and muscarinic regulation of striatal enkephalin and substance P messenger RNA following striatal dopamine denervation: effects of systemic and central administration of quin-pirole and scopolamine, Neuroscience, 63, 435, 1994.
86. Delfs, J.M. and Kelly, A.E., The role of D-l and D-2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum, Neuroscience, 39, 59, 1990.
87. Kilts, C.D., Anderson, C.M., Bissette, G., Ely, T.D. and Nemeroff, C.B., Differential effects of antipsychotic drugs on neurotensin content of discrete rat brain nuclei, Biochem. Pharmacol, 37, 1547, 1988.
88. Youngren, K.D., Moghaddam, B., Bunney, B.S. and Roth, R.H., Preferential activation of dopamine overflow by chronic clozapine treatment, Neuroscience Eett., 165: 41-44, 1994.
89. Chen, J., Ruan, D., Parades, W. and Gardener, E.L., Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving rats, Brain Res., 571, 135, 1992.
90. Vahid-Ansari F., Nakabeppu, Y. and Robertson, G.S., Contrasting effects of chronic clozapine, seroquel (ICI 204,636) and haloperidol administration on AFosB-like immunoreactivity in the rat forebrain, Neuroscience, in press.
91. Kebabian, J.W. and Caine, D.B., Multiple receptors for dopamine, Nature, 277, 93, 1979.
92. Civelli, O., Bunzow, J.R. and Grandy, D.K., Molecular diversity of the dopamine receptors, Annu. Rev. Pharmacol. Toxicol, 33, 281, 1993.
93. Sokoloff, R, Martres, M.-P, Giros, B., Bouthenet, M.-L. and Schwartz, J.-C., The third dopamine receptor (D3) as a novel target for antipsychotics, Biochem. Pharmacol, 43, 659, 1992.
94. Seeman, P. and VanTol, H.H.M., Dopamine receptor pharmacology. Trends Pharmacol Sci., 15: 264-, 1994.
95. 3 receptor, Basis and clinical aspects, Clin. Neuropharmacol, 16, 295, 1993.
96. Van Toi, H.H.M. and Seeman, R, The dopamine D4 receptor: a novel site for antipsychotic action, Clin. Neuropharmacol., 18, S143, 1995.
97. Landwehrmeyer, B., Mengod, G. and Palacios, J.M., Dopamine D3 receptor mRNA and binding sites in human brain, Mol. Brain Res., 18, 187, 1993.
98. Bouthenet, M.L., Souil, E., Martres, M.P., Sokoloff, P. and Schwartz, J.-C, Localization of D3 mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA, Brain Res., 564, 263, 1991.
99. Meador-Woodruff, J.H., Mansour, A., Saul, J. and Watson, S.J., Dopamine receptors and transporters: pharmacology, structure and function, in Neuroanatomical Distribution of Dopamine Receptor Messenger RNAs, Niznik, H.B., Ed., Marcel Dekker, New York, 1994, p. 401-414.
100. Seeman, P, Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4, Neuropsychopharmacology, 7, 261, 1992.
101. Waters, N., Lofberg, L., Haadsma-Svensson, S., Svensson, K., Sonesson, C. and Carlsson, A., Differential effects of dopamine D2 and D3 receptor antagonists in regard to release, in vivo receptor displacement and behavior, J. Neural Transm., 98, 39, 1994.
102. Griffon, N., Diaz, J., Levesque, D., Sautel, F., Schwartz, J.-C., Sokoloff, P, Simon, R, Constentin, J., Garrido, F., Mann, A. and Wermuth, C., Localization, regulation, and role of the dopamine D3 receptor are distinct from those of the D2 receptor, Clin. Neuropharmacol, 18, S130, 1995.
103. Waters, N., Svensson, K., Haadsma-Svensson, S.R., Smith, M.W. and Carlsson, A., The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity, J. Neural Transm., 94: 11, 1993.
104. Carter-Russell Hong, W.-J. and Surmeier, D.J., Coordinated expression of dopamine receptors (D1-D5) in single neostriatal neurons, Abstr. Soc. Neurosci, 21, 1425,1995.
105. Mohell, N.A., Sallemark, M., Rosqvist, S., Malmberg, A. and Jackson, D.M., Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors, Eur. J. Pharmacol, 238, 121, 1993.
106. Sesack, S.R., Deutch, A.Y., Roth, R.H. and Bunney, B.S., Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin, J. Comp. Neurol, 290, 213, 1992.
107. Diaz, J., Levesque, D., Griffon, N., Lammers, C.H., Martres, M.-R, Sokoloff, P. and Schwartz, J.-C., Opposing roles for D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens, Eur. J. Neurosci., 6, 1384, 1994.
108. Guo, N., Klitenick, M.A., Tham, C.S. and Fibiger, H.C., Receptor mechanism mediating clozapine-induced c-fos expression in the forebrain, Neuroscience, 65, 3, 747.
109. Tenbrink, R.E., Bergh, C., Duncan, J.N., Harris, D.W., Lahti, R.A., Lawson, C.F., Rees, S.A., Schlachter, S.K. and Smith, M.W., S(-)-4-[4-[2-(isochroman-l-yl)eth-yl]piperazin-l-yl]benzenesulfonamide, U-101387, a selective dopamine D4 antagonist, J. Med. Chem., in press.
110. Merchant, K.M., Gill, G.S., Harris, D.W., Huff, R.M., Lookingland, K.L., Lutzke, B.S., McCall, R.B., Piercey, M.F., Schreur, P.J.K.D., Sethy, V.H., Smith, M.W., Svensson, K.A., Tang, A.H., VonVoigtlander, P.F. and TenBrink, R.E., Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist, J. Pharmacol. Exp. Ther., submitted.
111. Garimella, B., Jazayeri, A., Spangler, C.S., Essani, K., Needham, L. and Merchant, K. M., Acute effects of concomitant D4 blockade on amphetamine-induced c-fos and NGFI-A mRNA expression in the rat forebrain, submitted.